000			nab a22 7a 4500
999			_c17084 _d17084
003			PC17084
005			20221122132911.0
008			221122b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9263 _aFernández Ruiz, Mario _eMedicina Interna
100			_9873 _aLumbreras Bermejo, Carlos _eMedicina Interna
100			_91388 _aArrazola Martínez, María Pilar _eMedicina Preventiva
100			_9162 _aLópez Medrano, Francisco _eEnfermedades Infecciosas
100			_91321 _aAndrés Belmonte, Amado _eNefrología
100			_9576 _aMorales Cerdán, José María _eNefrología
100			_91134 _aDe Juanes Pardo, José Ramón _d( -2014) _eMedicina Preventiva
100			_9876 _aAguado García, José María _eEnfermedades Infecciosas
245	0	0	_aImpact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients. _h[artículo]
260			_bTransplant infectious disease : an official journal of the Transplantation Society, _c2015
500			_aFormato Vancouver: Fernández Ruiz M, Lumbreras C, Arrazola MP, López Medrano F, Andrés A, Morales JM et al. Impact of squalene-based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients. Transpl Infect Dis. 2015 Apr;17(2):314-21. doi: 10.1111/tid.12355. Epub 2015 Mar 2. .
501			_aPMID: 25728936
504			_aContiene 30 referencias
520			_aBackground: Safety concerns have been raised about the use of adjuvanted vaccines after kidney transplantation. Methods: We retrospectively analyzed 65 kidney transplant (KT) recipients who received ≥1 dose of influenza vaccine (pandemic or seasonal) during the 2009-2010 campaign. Participants were classified into 2 groups: those who received a squalene-based AS03- or MF59-adjuvanted vaccine ("adjuvanted vaccination" [AV] group, n = 37) and those who exclusively received non-adjuvanted vaccines ("non-adjuvanted vaccination" [NAV] group, n = 28). Primary outcomes included occurrence of biopsy-proven acute graft rejection (BPAR) and graft function at months 6 and 12 after vaccination. Patients were followed up until graft loss, death, or October 2010. Results: Four episodes of BPAR occurred during post-vaccination follow-up, with no differences between the AV and NAV groups, in terms of cumulative incidence (5.4% vs. 7.1%, respectively; P = 0.581), incidence rate (0.22 vs. 0.18 episodes per 1000 transplant-days; P = 0.950), or occurrence of severe episodes (T-cell-mediated BPAR of grade ≥2a) (2.7% vs. 3.6%; P = 0.680). No between-group differences were seen in graft function after vaccination. Conclusion: Adjuvanted influenza vaccination in KT recipients seems to be safe regarding graft outcome.
710			_96 _aServicio de Medicina Interna
710			_982 _aServicio de Medicina Preventiva y Salud Pública
710			_986 _aServicio de Nefrología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17084.pdf _ySolicitar documento
942			_2ddc _cART _n0